Transgene Nec and BostonGene expand collaboration
Category: dates
Transgene Further Strengthens Management Team with Appointment of James Wentworth as Chief Business Officer
financial calendar 2024
Transgene Announces Financial Calendar for 2024
financial calendar 2024
Transgene and NEC Extend their Collaboration to Continue Joint Clinical Development of Neoantigen Cancer Vaccine TG4050
Transgene and NEC extend their collaboration
Transgene Announces Upcoming Investor Meetings
upcoming investor meetings
Transgene Strengthens its Leadership Team to Accelerate its Growth Strategy
nomination A Dubarry
Transgene reports business update and Q3 2023 financial position
Q3 2023 financial position
Transgene and BioInvent – First patient treated in Part B of Phase I trial assessing the novel oncolytic virus BT-001 in combination with KEYTRUDA®(pembrolizumab)
Transgene and BioInvent – first patient treated in Part B of Phase I trial
Transgene advances its innovative immunotherapy pipeline and extends financial visibility until the end of 2024
2023 half year results and business update
Transgene Announces Upcoming Investor Meetings
Transgene Announces Upcoming Investor Meetings